# Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)

> **NCT05388500** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Institut de cancérologie Strasbourg Europe** · enrollment: 800 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Paclitaxel + Trastuzumab
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT05388500
- **Lead sponsor:** Institut de cancérologie Strasbourg Europe
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-12-15
- **Primary completion:** 2030-12-15
- **Final completion:** 2030-12-15
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2022-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05388500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05388500, "Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT05388500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*